CAG-170: The Gut Bacteria That Keep Turning Up in Healthy People
Nobody has ever grown it in a laboratory. It is known only as the 170th cluster of genes that rise and fall together — and across 11,115 samples from 39 countries, there is consistently more of it in people who are well.
CAG-170 is a group of human gut bacteria known only from genetic data, reported in Cell Host & Microbe in February 2026 by a team led by Dr Alexandre Almeida at the University of Cambridge. Across 11,115 microbiome samples from 39 countries, levels were consistently higher in healthy people than in people with conditions including inflammatory bowel disease, obesity and chronic fatigue syndrome. Most species in the group have never been cultured, so there is no test for it and no probiotic containing it. The finding is an association across populations, not a diagnostic threshold for any individual.
Most of the bacteria in a human gut have never been grown in a laboratory. They are known the way a distant galaxy is known — by signal rather than by specimen, assembled from fragments of DNA rather than lifted from a dish. One such group now has a name, a number, and a strikingly consistent habit of turning up wherever people are well.
The findingWhat is CAG-170?
CAG-170 is a group of gut bacteria identified only from genetic data, never grown in a lab. In a study of 11,115 microbiome samples from 39 countries, it was present at higher levels in healthy people than in people with several chronic conditions.
The name is a filing label rather than a description. CAG stands for co-abundance gene group — a cluster of genes that consistently rise and fall together across samples, which is how researchers infer that they belong to the same organism without ever having isolated it. CAG-170 is simply the 170th such cluster catalogued. It belongs to what the Cambridge team calls the hidden microbiome: of roughly 4,600 gut bacterial species now recognised, more than 3,000 have never been cultured.
The studyHow large was the research, and what did it compare?
The work analysed 11,115 gut microbiome samples from more than 11,000 people across 39 countries, comparing healthy participants against people with 13 conditions including inflammatory bowel disease, colorectal cancer, Parkinson’s disease and multiple sclerosis.
Published in Cell Host & Microbe in February 2026 and led by Dr Alexandre Almeida of the Department of Veterinary Medicine at the University of Cambridge, the study searched for CAG-170’s genetic fingerprint across datasets drawn mostly from Europe, North America and Asia. Levels were consistently lower in samples from people with inflammatory bowel disease, obesity, chronic fatigue syndrome, and in samples showing general microbial imbalance.
Known only by its genetic fingerprint, catalogued as the 170th cluster of genes that rise and fall together, and more abundant almost everywhere people are well.
The chemistryWhat does CAG-170 appear to produce?
Genetic analysis indicates CAG-170 can make high levels of vitamin B12, along with enzymes that break down a wide range of carbohydrates, sugars and fibres. Researchers suspect the B12 mainly feeds other gut bacteria rather than the person.
That second point is the interesting one, and it is easy to misread. The obvious assumption — a gut bacterium making a vitamin humans need, therefore making it for humans — is not what the researchers proposed. Their reading is that CAG-170 functions more like infrastructure than like a supplement: B12 is a cofactor many other gut species depend on, and an organism supplying it steadily would help hold a wider community together. The enzymes point the same way, breaking down material that other microbes can then use.
The obstacleWhy can these bacteria not be grown in a laboratory?
Most CAG-170 species have resisted every attempt at culture. Gut bacteria are often adapted to conditions that are difficult to recreate — no oxygen, particular nutrients, and the presence of neighbouring species they depend on.
This is the practical bottleneck, and the researchers said so plainly: culturing methods will have to come first before any of this can be translated into an application. An organism nobody can grow cannot be tested, dosed, or manufactured. It can be counted, and that is currently the whole of what is possible.
The caveatDoes a low level of CAG-170 mean someone is unwell?
No. The study reports an association measured across populations, not a test that applies to an individual. It did not establish that low CAG-170 causes any condition, or that raising it would change anyone’s health.
This distinction does most of the work in microbiome research and is the first thing lost in summary. An association found by comparing thousands of samples describes a pattern in a population; it does not tell you the direction of the arrow. Lower levels in people with inflammatory bowel disease could mean the bacteria protect against it, or that the illness and its treatments alter the gut in ways that make life harder for CAG-170, or that some third factor moves both. The study was not designed to separate those, and its authors did not claim it was.
There is also no consumer test for CAG-170, no supplement containing it, and no established level to aim for. Almeida described the group as “a fundamental and underappreciated component of human health” — a statement about a research gap, not about anything a reader can currently act on.
The directionWhere does this line of work go next?
The researchers suggest CAG-170 could eventually serve as an indicator of gut microbiome health, and that the findings open a route toward probiotics designed to support it. Both possibilities depend on culturing the bacteria first.
It is worth noticing what kind of finding this is. Most microbiome headlines concern something a person might swallow. This one concerns the map itself — the recognition that a majority of the organisms in the human gut are still catalogue entries rather than known species, and that at least one of the unnamed ones tracks health closely enough to be worth the effort of finding out what it is.